2.1 Cardiovascular I: Ischemic, Heart Failure & Vascular
Key Takeaways
- Cardiovascular is the single largest PANRE blueprint category at 12% of scored content, so ischemic heart disease, heart failure, hypertension, and vascular disease carry high yield.
- Distinguish unstable angina, NSTEMI, and STEMI by symptoms, troponin, and ECG: STEMI needs emergent reperfusion while UA/NSTEMI is risk-stratified for early invasive versus ischemia-guided strategy.
- Heart failure management hinges on ejection fraction: guideline-directed medical therapy for reduced EF includes an ARNI or ACE inhibitor/ARB, an evidence-based beta blocker, a mineralocorticoid receptor antagonist, and an SGLT2 inhibitor.
- Hypertension is staged by confirmed out-of-office or repeated office readings, and management combines lifestyle change with first-line agents (thiazide-type diuretic, ACE inhibitor/ARB, or calcium channel blocker).
- Statin therapy intensity is chosen by clinical ASCVD, severe LDL elevation, diabetes, or estimated 10-year risk rather than by an LDL number alone.
Why Ischemic, Failure, and Vascular Disease Dominate the Exam
The Cardiovascular System is the largest single category on the PANRE (Physician Assistant National Recertifying Examination) blueprint at 12% of scored content. Because this section reviews recertification-level clinical reasoning, expect vignettes that ask you to diagnose a presentation, choose first-line therapy, recognize a contraindication, and decide disposition rather than recall isolated facts.
This section covers four high-yield clusters: coronary artery disease (CAD) and acute coronary syndrome (ACS), heart failure (HF), hypertension (HTN), and peripheral and aortic vascular disease, plus lipid management that ties them together. The recurring exam skill is matching a clinical pattern to the next best step.
Coronary Artery Disease and Acute Coronary Syndrome
Stable angina is predictable, exertional chest discomfort relieved by rest or nitroglycerin and reflects fixed coronary stenosis with demand-driven ischemia. Acute coronary syndrome is the spectrum of plaque rupture and thrombosis: unstable angina (UA), non-ST-elevation myocardial infarction (NSTEMI), and ST-elevation myocardial infarction (STEMI).
The diagnostic triad is symptoms, electrocardiogram (ECG), and cardiac troponin. Unstable angina has ischemic symptoms without troponin elevation. NSTEMI adds a rise in troponin without persistent ST elevation. STEMI shows persistent ST-segment elevation or a new left bundle branch block with a troponin rise, and it indicates acute transmural injury requiring emergent reperfusion.
Initial Stabilization
For suspected ACS, the early bundle commonly includes aspirin, antianginal nitrates when not contraindicated, oxygen only if hypoxic, and analgesia, with anticoagulation and a second antiplatelet agent guided by the planned strategy. A STEMI pathway prioritizes timely percutaneous coronary intervention (PCI), or fibrinolytics when timely PCI is unavailable. UA/NSTEMI patients are risk-stratified to an early invasive versus ischemia-guided approach.
Secondary Prevention
After ACS, long-term therapy typically layers an antiplatelet regimen, a high-intensity statin, a beta blocker, and an ACE inhibitor or angiotensin receptor blocker (ARB) when there is reduced ejection fraction, hypertension, or diabetes, alongside structured cardiac rehabilitation and risk-factor control.
| Condition | Typical Presentation | PA-Level Management Focus |
|---|---|---|
| Stable angina | Predictable exertional chest pain relieved by rest/nitroglycerin | Risk-factor control, antianginal therapy, statin, evaluate for ischemia testing |
| Unstable angina | New, worsening, or rest angina; troponin not elevated | Admit, antithrombotic therapy, risk-stratify for invasive vs ischemia-guided care |
| NSTEMI | Ischemic symptoms with troponin rise, no persistent ST elevation | Antithrombotic therapy, risk stratification, often early invasive strategy |
| STEMI | Ischemic symptoms with persistent ST elevation/new LBBB | Emergent reperfusion (primary PCI preferred; fibrinolysis if PCI delayed) |
Heart Failure
Classify heart failure by left ventricular ejection fraction (LVEF): heart failure with reduced ejection fraction (HFrEF) and heart failure with preserved ejection fraction (HFpEF), with a mildly reduced range in between. B-type natriuretic peptide (BNP) or NT-proBNP supports the diagnosis when the cause of dyspnea is unclear, and echocardiography defines structure and EF.
Left-sided failure produces dyspnea, orthopnea, paroxysmal nocturnal dyspnea, and pulmonary congestion. Right-sided failure produces jugular venous distension, peripheral edema, and hepatic congestion. Acute decompensation is treated with diuresis, oxygenation/ventilatory support as needed, and treatment of the precipitant (ischemia, arrhythmia, nonadherence, or uncontrolled hypertension).
Guideline-Directed Medical Therapy for HFrEF
For chronic HFrEF, foundational drug classes include an angiotensin receptor-neprilysin inhibitor (ARNI) or ACE inhibitor/ARB, an evidence-based beta blocker, a mineralocorticoid receptor antagonist (MRA), and a sodium-glucose cotransporter-2 (SGLT2) inhibitor, with diuretics for congestion. For HFpEF, control blood pressure, manage volume and comorbidities, and use an SGLT2 inhibitor as supported by current evidence.
Hypertension
Hypertension is staged using confirmed out-of-office readings or repeated, properly measured office readings rather than a single elevated value. Evaluate for target-organ damage and secondary causes when the pattern is atypical (young age, resistant disease, or abrupt onset).
Management pairs lifestyle modification (sodium reduction, the DASH dietary pattern, weight loss, physical activity, and limiting alcohol) with pharmacotherapy. First-line drug classes are a thiazide-type diuretic, an ACE inhibitor or ARB (do not combine the two), or a dihydropyridine calcium channel blocker (CCB). Choose by comorbidity: ACE inhibitor/ARB favored with diabetic kidney disease or HFrEF; beta blockers are added for a compelling indication such as post-MI or HFrEF rather than as routine monotherapy.
Peripheral and Aortic Vascular Disease
Peripheral artery disease (PAD) presents as exertional calf claudication, diminished pulses, and an abnormal ankle-brachial index (ABI). Management is structured exercise, smoking cessation, a statin, antiplatelet therapy, and revascularization for limiting or threatening symptoms.
Abdominal aortic aneurysm (AAA) is often asymptomatic and found on imaging or screening ultrasound; small aneurysms are surveilled while a large or symptomatic aneurysm is referred for repair. A pulsatile abdominal mass with hypotension and pain suggests rupture and is a surgical emergency. Acute aortic dissection presents with abrupt severe tearing chest or back pain and possible pulse or blood-pressure differential; management controls heart rate and blood pressure and obtains emergent imaging and surgical evaluation.
Lipid Management
Statin intensity is selected by clinical category rather than by chasing a single number: established clinical atherosclerotic cardiovascular disease (ASCVD), very high baseline low-density lipoprotein (LDL) cholesterol, diabetes, or an elevated estimated 10-year ASCVD risk. Lifestyle therapy is universal, and non-statin add-on agents are considered when LDL lowering is insufficient on a maximally tolerated statin in higher-risk patients.
A 58-year-old presents with 40 minutes of crushing substernal chest pain radiating to the jaw. The ECG shows 3 mm of ST-segment elevation in leads II, III, and aVF. Which management priority is most appropriate?
A patient with chronic heart failure has an LVEF of 30%, NYHA class II symptoms, and is already on an ACE inhibitor and a beta blocker. Which addition best reflects guideline-directed medical therapy for HFrEF?
A 64-year-old smoker reports reproducible right calf pain after walking two blocks that resolves with rest, with diminished pedal pulses and a reduced ankle-brachial index. Which initial management plan is most appropriate?
Which statement best reflects a risk-based approach to statin therapy on the PANRE?